RE: Rohm & Haas Co. (ROH) by Dow Chemical Co. (DOW)
Acquirer: DOW
Target: ROH
Offer per share: $78 cash
Target share price: $56.76
Expected closing: 1/15/2009
ROI: 37.42%
Annualized gain: off the charts
The reason for the huge gap is the dumping of the Kuwait/DOW partnership this past weekend. Many feel the deal for ROH will get cancelled, since DOW was counting [...]
Well, looks like I am going to lose on my decision to buy HUN for the short term. They announced the deal was killed today, with Hexion paying break fees to HUN ($750M cash, $250M notes).
I went against my gut and held, when I should have sold earlier (I wrote about maybe getting out of [...]
It’s official… atleast as far as current shareholders are concerned. They approved the deal recently and looks like it will close no later than Jan 7, 2009. That’s good news for me, as my entry point shows here:
Entry Price: $65.34
Deal Price: $69.50
My ROI will be: 6.4% (27.6% annualized if it close on Jan 7, 2009)
Source:
Press [...]
Eli Lilly has completed its tender offer for ImClone Systems. I had this one in my simulated portfolio. Here’s how I made out:
Entry Date: 10/10/2008
Entry Price: $65.00
Tender off price: $70.00
Deal closed: 11/24/2008
ROI: 7.69%
Annualized Return: 62.9%
Not bad! If I had added this one to my real money port, I most likely would have been in for [...]
Reuters reports that Roche’s ability to raise funding for the Genentech merger are in doubt.
“…In light of the current climate, a $45 billion loan looks large. It would have to be a combination of everything — Roche would have to print bonds to get the deal done,” a senior banker close to the deal said.”
“…I [...]
